Welcome to our dedicated page for PDL BioPharma news (Ticker: PDLI), a resource for investors and traders seeking the latest updates and insights on PDL BioPharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PDL BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PDL BioPharma's position in the market.
PDL BioPharma announced a settlement agreement with Defined Diagnostics, LLC, resolving litigation over $44.1 million in loans made in August 2013. The Wellstat Parties will pay $7.5 million upfront, followed by either $5 million by February 2021 and $55 million by July 2021 or a single payment of $67.5 million by the same date. If payments are not fulfilled, PDL can record judgment for $92.5 million. This settlement aims to enhance PDL's monetization strategy and potentially increase distributions to shareholders.
PDL BioPharma reported its financial results for Q2 and H1 2020, highlighting a GAAP net loss of $50 million, or $0.43 per share, compared to a loss of $4.4 million, or $0.04 per share, a year earlier. Revenues of $5.2 million were primarily driven by LENSAR but showed a 31% decline year-over-year due to COVID-19 impacts. The company is pursuing a monetization strategy and plans to dissolve under Delaware law. It has made significant transactions, including a potential spin-off of LENSAR and a definitive agreement to sell Noden Pharma for up to $48.25 million.
PDL BioPharma, Inc. (Nasdaq: PDLI) will release its Q2 2020 financial results on August 6, 2020, after market close. A conference call and webcast will be held at 4:30 p.m. ET to discuss the results. Participants can pre-register for immediate access to the call. PDL has shifted its focus to monetizing its portfolio assets to benefit shareholders. The upcoming earnings release will provide insights into the company's financial health and operational developments.
PDL BioPharma has signed a definitive agreement to sell its subsidiaries, Noden Pharma DAC and Noden USA, to Stanley Capital for up to $48.25 million. The initial cash payment expected at closing is $12.0 million, followed by $33 million in quarterly payments until October 2023. Additionally, there may be contingent payments totaling $3.25 million. This transaction reflects PDL's ongoing monetization strategy, aiming to maximize shareholder value. The deal is anticipated to close in August 2020, pending customary conditions.